Black Diamond Therapeutics
Develops brain-penetrant therapies for EGFR-mutant lung cancer and glioblastoma.
$2.23
After-hours close0.00 (0.00%)
At close$2.23(−1.76%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 67.21%38.51M sharesInsiders 0.26%147.6K sharesOther 32.53%18.64M shares
Shares outstanding 57.30M · Float 46.02M · 80.3% free float
Institutions13F, as of Mar 31, 2026
108 holders · 38.51M shares · 23 new positions · 54 increased · 33 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.56M | 18.43% | −43.5K | May 15, 2026 |
| Nea Management Company, LLC | 4.45M | 7.76% | 0 | May 15, 2026 |
| Acadian Asset Management LLC | 2.35M | 4.10% | +718.5K | May 13, 2026 |
| Vanguard Capital Management LLC | 1.85M | 3.23% | +1.85Mnew | May 15, 2026 |
| Renaissance Technologies LLC | 1.64M | 2.87% | +694.0K | May 14, 2026 |
| Dimensional Fund Advisors LP | 1.30M | 2.27% | +444.6K | May 7, 2026 |
| BlackRock, Inc. | 1.11M | 1.93% | +218.6K | May 13, 2026 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.06M | 1.85% | +403.7K | May 11, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Ryan Wilderincl. Vestal Point Capital, LP | 8.90% | 5.03M | 13G | Nov 14, 2024 ↗ |
| BlackRock, Inc. | 6.70% | 3.84M | 13G | Jul 27, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Biotech Growth N V | 10 percent owner | 2.73M | 4.77% | Mar 20, 2025 |
| Ali Behbahani | director | 102.5K | 0.18% | Jun 22, 2026 |
| Prakash Raman | director | 45.0K | 0.08% | Jun 22, 2026 |
4 ten-percent owners hold 7.41M shares by Form 4, outside the officers-and-directors figure above · 17 people have not refiled in the last 18 months (9.17M shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.